Cargando…

Esculetin Alleviates Acute Liver Failure following Lipopolysaccharide/D-Galactosamine in Male C57BL/6 Mice

BACKGROUND: Acute liver failure (ALF) is a fatal clinical situation that rapidly leads to the loss of normal liver function. Esculetin is a natural herbal compound used for the management of various diseases such as cardiovascular and renal disorders. In this study, we evaluated the protective effec...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohamadi-Zarch, Seyed-Mahdi, Baluchnejadmojarad, Tourandokht, Nourabadi, Davood, Ramazi, Samira, Nazari-Serenjeh, Morteza, Roghani, Mehrdad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Shiraz University of Medical Sciences 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8438341/
https://www.ncbi.nlm.nih.gov/pubmed/34539012
http://dx.doi.org/10.30476/ijms.2020.84909.1474
_version_ 1783752350872109056
author Mohamadi-Zarch, Seyed-Mahdi
Baluchnejadmojarad, Tourandokht
Nourabadi, Davood
Ramazi, Samira
Nazari-Serenjeh, Morteza
Roghani, Mehrdad
author_facet Mohamadi-Zarch, Seyed-Mahdi
Baluchnejadmojarad, Tourandokht
Nourabadi, Davood
Ramazi, Samira
Nazari-Serenjeh, Morteza
Roghani, Mehrdad
author_sort Mohamadi-Zarch, Seyed-Mahdi
collection PubMed
description BACKGROUND: Acute liver failure (ALF) is a fatal clinical situation that rapidly leads to the loss of normal liver function. Esculetin is a natural herbal compound used for the management of various diseases such as cardiovascular and renal disorders. In this study, we evaluated the protective effects of esculetin in a mouse model of ALF. METHODS: This article is a report on an experimental study that was conducted at Iran University of Medical Sciences in 2019. Forty-eight male C57BL/6 mice were randomly divided into control, LPS/D-Gal, and LPS/D-Gal+Esculetin (40 mg/kg) groups (n=16 per group). ALF was induced with an intraperitoneal injection of lipopolysaccharide (LPS)/D-galactosamine (D-Gal).The LPS/D-Gal group received a mixture of LPS (50 μg/kg) and D-Gal (400 mg/kg). The LPS/D-Gal+Esculetin group received esculetin by gavage 24 hours and one hour before receiving LPS/D-Gal. Six hours after LPS/D-Gal injection, the mice were sacrificed. Liver injury markers, including alanine aminotransferase (ALT), aspartate transaminase (AST), and alkaline phosphatase (ALP), were measured in the serum. Oxidative stress indices and inflammatory markers such as interleukin-1 beta (IL-1β), IL-6, and tumor necrosis factor-alpha (TNF-α) were measured in hepatic tissue. The histopathology of liver tissue was also assessed. The data were analyzed using one-way ANOVA, followed by the post hoc Tukey test. RESULTS: Esculetin lowered oxidative stress and myeloperoxidase activity (P<0.001); reduced the serum levels of ALT (P=0.037), AST (P=0.032), and ALP (P=0.004); and decreased the hepatic levels of IL-1β (P=0.002), IL-6 (P=0.004), toll-like receptor 4 (P<0.001), TNF-α (P=0.003), and nuclear factor-kappa B (P<0.001) as compared with LPS/D-Gal. Additionally, esculetin ameliorated hepatic tissue injury following LPS/D-Gal challenge. CONCLUSION: Esculetin can reduce liver injury through the mitigation of oxidative burden, inflammation, and neutrophil infiltration and also exerts hepatoprotective effects against ALF.
format Online
Article
Text
id pubmed-8438341
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Shiraz University of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-84383412021-09-17 Esculetin Alleviates Acute Liver Failure following Lipopolysaccharide/D-Galactosamine in Male C57BL/6 Mice Mohamadi-Zarch, Seyed-Mahdi Baluchnejadmojarad, Tourandokht Nourabadi, Davood Ramazi, Samira Nazari-Serenjeh, Morteza Roghani, Mehrdad Iran J Med Sci Original Article BACKGROUND: Acute liver failure (ALF) is a fatal clinical situation that rapidly leads to the loss of normal liver function. Esculetin is a natural herbal compound used for the management of various diseases such as cardiovascular and renal disorders. In this study, we evaluated the protective effects of esculetin in a mouse model of ALF. METHODS: This article is a report on an experimental study that was conducted at Iran University of Medical Sciences in 2019. Forty-eight male C57BL/6 mice were randomly divided into control, LPS/D-Gal, and LPS/D-Gal+Esculetin (40 mg/kg) groups (n=16 per group). ALF was induced with an intraperitoneal injection of lipopolysaccharide (LPS)/D-galactosamine (D-Gal).The LPS/D-Gal group received a mixture of LPS (50 μg/kg) and D-Gal (400 mg/kg). The LPS/D-Gal+Esculetin group received esculetin by gavage 24 hours and one hour before receiving LPS/D-Gal. Six hours after LPS/D-Gal injection, the mice were sacrificed. Liver injury markers, including alanine aminotransferase (ALT), aspartate transaminase (AST), and alkaline phosphatase (ALP), were measured in the serum. Oxidative stress indices and inflammatory markers such as interleukin-1 beta (IL-1β), IL-6, and tumor necrosis factor-alpha (TNF-α) were measured in hepatic tissue. The histopathology of liver tissue was also assessed. The data were analyzed using one-way ANOVA, followed by the post hoc Tukey test. RESULTS: Esculetin lowered oxidative stress and myeloperoxidase activity (P<0.001); reduced the serum levels of ALT (P=0.037), AST (P=0.032), and ALP (P=0.004); and decreased the hepatic levels of IL-1β (P=0.002), IL-6 (P=0.004), toll-like receptor 4 (P<0.001), TNF-α (P=0.003), and nuclear factor-kappa B (P<0.001) as compared with LPS/D-Gal. Additionally, esculetin ameliorated hepatic tissue injury following LPS/D-Gal challenge. CONCLUSION: Esculetin can reduce liver injury through the mitigation of oxidative burden, inflammation, and neutrophil infiltration and also exerts hepatoprotective effects against ALF. Shiraz University of Medical Sciences 2021-09 /pmc/articles/PMC8438341/ /pubmed/34539012 http://dx.doi.org/10.30476/ijms.2020.84909.1474 Text en Copyright: © Iranian Journal of Medical Sciences https://creativecommons.org/licenses/by-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 4.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Mohamadi-Zarch, Seyed-Mahdi
Baluchnejadmojarad, Tourandokht
Nourabadi, Davood
Ramazi, Samira
Nazari-Serenjeh, Morteza
Roghani, Mehrdad
Esculetin Alleviates Acute Liver Failure following Lipopolysaccharide/D-Galactosamine in Male C57BL/6 Mice
title Esculetin Alleviates Acute Liver Failure following Lipopolysaccharide/D-Galactosamine in Male C57BL/6 Mice
title_full Esculetin Alleviates Acute Liver Failure following Lipopolysaccharide/D-Galactosamine in Male C57BL/6 Mice
title_fullStr Esculetin Alleviates Acute Liver Failure following Lipopolysaccharide/D-Galactosamine in Male C57BL/6 Mice
title_full_unstemmed Esculetin Alleviates Acute Liver Failure following Lipopolysaccharide/D-Galactosamine in Male C57BL/6 Mice
title_short Esculetin Alleviates Acute Liver Failure following Lipopolysaccharide/D-Galactosamine in Male C57BL/6 Mice
title_sort esculetin alleviates acute liver failure following lipopolysaccharide/d-galactosamine in male c57bl/6 mice
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8438341/
https://www.ncbi.nlm.nih.gov/pubmed/34539012
http://dx.doi.org/10.30476/ijms.2020.84909.1474
work_keys_str_mv AT mohamadizarchseyedmahdi esculetinalleviatesacuteliverfailurefollowinglipopolysaccharidedgalactosamineinmalec57bl6mice
AT baluchnejadmojaradtourandokht esculetinalleviatesacuteliverfailurefollowinglipopolysaccharidedgalactosamineinmalec57bl6mice
AT nourabadidavood esculetinalleviatesacuteliverfailurefollowinglipopolysaccharidedgalactosamineinmalec57bl6mice
AT ramazisamira esculetinalleviatesacuteliverfailurefollowinglipopolysaccharidedgalactosamineinmalec57bl6mice
AT nazariserenjehmorteza esculetinalleviatesacuteliverfailurefollowinglipopolysaccharidedgalactosamineinmalec57bl6mice
AT roghanimehrdad esculetinalleviatesacuteliverfailurefollowinglipopolysaccharidedgalactosamineinmalec57bl6mice